<p>Lifecore Biomedical（纳斯达克：LFCR - 获取免费报告）可能将在 2026 年 1 月 1 日星期四市场收盘后发布其 2026 年第二季度财报。分析师预计 Lifecore Biomedical 本季度每股收益为（$0.11），收入为 3530.80 万美元。有兴趣的人可以在公司即将发布的 2026 年第二季度财报页面找到电话会议的详细信息，最新的电话会议安排在 2026 年 1 月 2 日星期五东部时间凌晨 12:00。</p>
<p>获取 <strong>Lifecore Biomedical</strong> 的提醒：</p>
<p>Lifecore Biomedical（纳斯达克：LFCR - 获取免费报告）上一次发布季度财报是在 4 月 1 日星期一。该公司报告本季度每股收益（EPS）为（$0.22）。Lifecore Biomedical 的股本回报率为负的 1211.09%，净利润率为负的 25.59%。该公司本季度的收入为 2654 万美元。分析师平均预计 Lifecore Biomedical 在当前财政年度的每股收益为-$1，下一财政年度的每股收益也为-$1。</p>
<h2>Lifecore Biomedical 股票表现</h2>
<p>纳斯达克：LFCR 在星期四开盘价为$8.24。该公司的市值为 3.0875 亿美元，市盈率为-7.70，贝塔值为 0.60。该公司的 50 日简单移动平均为$7.48，200 日简单移动平均为$7.45。该公司的债务与股本比率为 113.76，流动比率为 2.80，速动比率为 1.67。Lifecore Biomedical 的 1 年最低价为$4.76，1 年最高价为$8.85。</p>
<h2>华尔街分析师观点</h2>
<p>几位股票研究分析师对该股票发表了评论。Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 Lifecore Biomedical 股票的 “卖出（d）” 评级。KeyCorp 在 9 月 3 日星期三的研究报告中开始覆盖 Lifecore Biomedical 的股票。他们对该公司的评级为 “行业权重”。一位投资分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Lifecore Biomedical 目前的共识评级为 “持有”，平均目标价为$6.00。</p>
<p><strong>阅读我们关于 Lifecore Biomedical 的最新报告</strong></p>
<h2>机构投资者对 Lifecore Biomedical 的看法</h2>
<p>对冲基金最近增加或减少了在该公司的股份。Quarry LP 在第三季度购买了价值$28,000 的 Lifecore Biomedical 新股份。BNP Paribas 金融市场在第三季度将其在 Lifecore Biomedical 的股份增加了 92.7%。BNP Paribas 金融市场现在拥有 5791 股该公司的股票，价值$43,000，此前在上个季度又购买了 2786 股。怀俄明州购买了价值约$69,000 的 Lifecore Biomedical 新股份。制造商人寿保险公司在第二季度购买了价值$88,000 的 Lifecore Biomedical 新股份。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Lifecore Biomedical 的持股增加了 14.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 14785 股该公司的股票，价值$104,000，此前在上个季度又购买了 1886 股。机构投资者持有该公司 83.36% 的股份。</p>
<h2>Lifecore Biomedical 公司简介</h2>
<p>（获取免费报告）</p>
<p>Lifecore Biomedical, Inc 是一家公开交易的专业生物制药公司，总部位于明尼苏达州查斯卡。该公司专注于开发、制造和商业化基于透明质酸（HA）的产品，以满足医疗和美容需求。Lifecore 的专有 HA 配方旨在满足高度监管市场对纯度、一致性和性能的严格监管标准。</p>
<p>该公司的产品组合涵盖多个治疗领域，包括眼科、骨科、皮肤科和伤口护理。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Lifecore Biomedical 更好</li>
<li>请勿删除，立即阅读</li>
<li>崩盘前一个月</li>
<li>麦当劳的秘密</li>
<li>家族信托如何帮助保护您的财富</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZDUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZDUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资$1,000 在 Lifecore Biomedical 吗？</h2>
<p>在您考虑 Lifecore Biomedical 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Lifecore Biomedical 并不在名单上。</p>
<p>虽然 Lifecore Biomedical 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LFCR

<p>Lifecore Biomedical（纳斯达克代码：LFCR）将在 1 月 1 日市场收盘后发布 2026 年第二季度财报。分析师预计每股收益为（$0.11），收入为 3530.8 万美元。该公司之前报告的每股收益为（$0.22），收入为 2654 万美元。Lifecore 的股票开盘价为$8.24，市值为 3.0875 亿美元。分析师给予该股票的共识评级为 “持有”，平均目标价为$6.00。机构投资者持有该股票的 83.36%</p>

<p>Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) will likely be releasing its Q2 2026 results after the market closes on Thursday, January 1st. Analysts expect Lifecore Biomedical to post earnings of ($0.11) per share and revenue of $35.3080 million for the quarter. Interested persons can find conference call details on the company's upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, January 2, 2026 at 12:00 AM ET.</p>
<div class="lb-trans"><p>Lifecore Biomedical（纳斯达克：LFCR - 获取免费报告）可能将在 2026 年 1 月 1 日星期四市场收盘后发布其 2026 年第二季度财报。分析师预计 Lifecore Biomedical 本季度每股收益为（$0.11），收入为 3530.80 万美元。有兴趣的人可以在公司即将发布的 2026 年第二季度财报页面找到电话会议的详细信息，最新的电话会议安排在 2026 年 1 月 2 日星期五东部时间凌晨 12:00。</p>
</div><p>Get <strong>Lifecore Biomedical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Lifecore Biomedical</strong> 的提醒：</p>
</div><p>Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its quarterly earnings data on Monday, April 1st. The company reported ($0.22) earnings per share (EPS) for the quarter. Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 25.59%.The company had revenue of $26.54 million for the quarter. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Lifecore Biomedical（纳斯达克：LFCR - 获取免费报告）上一次发布季度财报是在 4 月 1 日星期一。该公司报告本季度每股收益（EPS）为（$0.22）。Lifecore Biomedical 的股本回报率为负的 1211.09%，净利润率为负的 25.59%。该公司本季度的收入为 2654 万美元。分析师平均预计 Lifecore Biomedical 在当前财政年度的每股收益为-$1，下一财政年度的每股收益也为-$1。</p>
</div><h2>Lifecore Biomedical Stock Performance</h2>
<div class="lb-trans"><h2>Lifecore Biomedical 股票表现</h2>
</div><p>NASDAQ:LFCR opened at $8.24 on Thursday. The company has a market capitalization of $308.75 million, a P/E ratio of -7.70 and a beta of 0.60. The business has a fifty day simple moving average of $7.48 and a two-hundred day simple moving average of $7.45. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.80 and a quick ratio of 1.67. Lifecore Biomedical has a 1 year low of $4.76 and a 1 year high of $8.85.</p>
<div class="lb-trans"><p>纳斯达克：LFCR 在星期四开盘价为$8.24。该公司的市值为 3.0875 亿美元，市盈率为-7.70，贝塔值为 0.60。该公司的 50 日简单移动平均为$7.48，200 日简单移动平均为$7.45。该公司的债务与股本比率为 113.76，流动比率为 2.80，速动比率为 1.67。Lifecore Biomedical 的 1 年最低价为$4.76，1 年最高价为$8.85。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities research analysts have commented on the stock. Weiss Ratings reaffirmed a &#34;sell (d)&#34; rating on shares of Lifecore Biomedical in a report on Wednesday, October 8th. KeyCorp assumed coverage on shares of Lifecore Biomedical in a research note on Wednesday, September 3rd. They issued a &#34;sector weight&#34; rating for the company. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Lifecore Biomedical currently has a consensus rating of &#34;Hold&#34; and an average price target of $6.00.</p>
<div class="lb-trans"><p>几位股票研究分析师对该股票发表了评论。Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 Lifecore Biomedical 股票的 “卖出（d）” 评级。KeyCorp 在 9 月 3 日星期三的研究报告中开始覆盖 Lifecore Biomedical 的股票。他们对该公司的评级为 “行业权重”。一位投资分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Lifecore Biomedical 目前的共识评级为 “持有”，平均目标价为$6.00。</p>
</div><p><strong>Read Our Latest Report on Lifecore Biomedical</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Lifecore Biomedical 的最新报告</strong></p>
</div><h2>Institutional Investors Weigh In On Lifecore Biomedical</h2>
<div class="lb-trans"><h2>机构投资者对 Lifecore Biomedical 的看法</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the company. Quarry LP bought a new stake in Lifecore Biomedical during the 3rd quarter valued at $28,000. BNP Paribas Financial Markets boosted its stake in Lifecore Biomedical by 92.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company's stock worth $43,000 after purchasing an additional 2,786 shares in the last quarter. State of Wyoming bought a new position in shares of Lifecore Biomedical in the second quarter worth approximately $69,000. The Manufacturers Life Insurance Company purchased a new stake in Lifecore Biomedical during the 2nd quarter valued at $88,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Lifecore Biomedical by 14.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company's stock worth $104,000 after buying an additional 1,886 shares in the last quarter. Institutional investors own 83.36% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近增加或减少了在该公司的股份。Quarry LP 在第三季度购买了价值$28,000 的 Lifecore Biomedical 新股份。BNP Paribas 金融市场在第三季度将其在 Lifecore Biomedical 的股份增加了 92.7%。BNP Paribas 金融市场现在拥有 5791 股该公司的股票，价值$43,000，此前在上个季度又购买了 2786 股。怀俄明州购买了价值约$69,000 的 Lifecore Biomedical 新股份。制造商人寿保险公司在第二季度购买了价值$88,000 的 Lifecore Biomedical 新股份。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Lifecore Biomedical 的持股增加了 14.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 14785 股该公司的股票，价值$104,000，此前在上个季度又购买了 1886 股。机构投资者持有该公司 83.36% 的股份。</p>
</div><h2>Lifecore Biomedical Company Profile</h2>
<div class="lb-trans"><h2>Lifecore Biomedical 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.</p>
<div class="lb-trans"><p>Lifecore Biomedical, Inc 是一家公开交易的专业生物制药公司，总部位于明尼苏达州查斯卡。该公司专注于开发、制造和商业化基于透明质酸（HA）的产品，以满足医疗和美容需求。Lifecore 的专有 HA 配方旨在满足高度监管市场对纯度、一致性和性能的严格监管标准。</p>
</div><p>The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.</p>
<div class="lb-trans"><p>该公司的产品组合涵盖多个治疗领域，包括眼科、骨科、皮肤科和伤口护理。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Lifecore Biomedical</li>
<li>Do not delete, read immediately</li>
<li>A month before the crash</li>
<li>The McDonald's Secret</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Lifecore Biomedical 更好</li>
<li>请勿删除，立即阅读</li>
<li>崩盘前一个月</li>
<li>麦当劳的秘密</li>
<li>家族信托如何帮助保护您的财富</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZDUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=LFCR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lifecore Biomedical Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资$1,000 在 Lifecore Biomedical 吗？</h2>
</div><p>Before you consider Lifecore Biomedical, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Lifecore Biomedical 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lifecore Biomedical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Lifecore Biomedical 并不在名单上。</p>
</div><p>While Lifecore Biomedical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Lifecore Biomedical 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Lifecore Biomedical (LFCR) 预计将在周四发布季度财报